Literature DB >> 7497767

The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group.

S D Ramsey1, D L Patrick, R K Albert, E B Larson, D E Wood, G Raghu.   

Abstract

OBJECTIVE: Lung transplantation is one of the fastest-growing solid organ transplant procedures in the world, yet its cost-effectiveness is unknown. We compared the costs and outcomes of the first 25 patients who received lung transplants at the University of Washington with 24 patients currently on the lung transplant waiting list.
DESIGN: Inpatient and outpatient charges were obtained from the hospital billing service and home health agencies. Quality-adjusted life year scores (QALYs) were computed from the following: (1) utility scores obtained through standard gamble interviews, and (2) published survival data from an international lung transplant registry and from studies of patients on lung transplant waiting lists.
RESULTS: Transplantation charges averaged $164,989 (median, $152,071). Average monthly charges posttransplant were $11,917 in year 1 and $4,525 thereafter, vs $3,395 for waiting-list patients. Posttransplant utility scores were significantly higher than waiting-list scores (0.80 vs 0.68; p < 0.001). Life expectancy was not greater for lung transplant vs waiting-list patients (5.89 vs 5.32 years; p > 0.05), although quality-adjusted life expectancy did improve significantly. After converting charges to costs, the incremental cost per QALY gained for posttransplant compared with waiting-list patients was $176,817.
CONCLUSIONS: Lung transplantation is very expensive, although it can substantially improve quality of life. Two-thirds of care costs are incurred after transplantation. The principal barriers to cost-effectiveness at present are the high cost of postrecovery care and marginal gains in life expectancy compared with conservative care.

Entities:  

Mesh:

Year:  1995        PMID: 7497767     DOI: 10.1378/chest.108.6.1594

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

Review 1.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

Authors:  Pamela Samson; Aalok Patel; Cliff G Robinson; Daniel Morgensztern; Su-Hsin Chang; Graham A Colditz; Saiama Waqar; Traves D Crabtree; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-08-25       Impact factor: 4.330

3.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.

Authors:  Akiko M Saito; Corey Cutler; David Zahrieh; Robert J Soiffer; Vincent T Ho; Edwin P Alyea; John Koreth; Joseph H Antin; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

Review 4.  Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease.

Authors:  Namrata Patel; Malcolm DeCamp; Gerard J Criner
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 5.  Lung transplantation. Part II. Postoperative management and results.

Authors:  D E Wood; G Raghu
Journal:  West J Med       Date:  1997-01

6.  Increased resource use in lung transplant admissions in the lung allocation score era.

Authors:  Bryan G Maxwell; Joshua J Mooney; Peter H U Lee; Joseph E Levitt; Laveena Chhatwani; Mark R Nicolls; Martin R Zamora; Vincent Valentine; David Weill; Gundeep S Dhillon
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

7.  Vascularized composite allograft transplant survival in miniature swine: is MHC tolerance sufficient for acceptance of epidermis?

Authors:  Curtis L Cetrulo; Radbeh Torabi; Joseph R Scalea; Akira Shimizu; Angelo A Leto Barone; Bradford C Gillon; Masayuki Tasaki; David A Leonard; Taylor A Cormack; Vincenzo Villani; Mark A Randolph; David H Sachs; Kazuhiko Yamada
Journal:  Transplantation       Date:  2013-12-15       Impact factor: 4.939

8.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12

9.  Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells.

Authors:  Aric L Gregson; Aki Hoji; Vyacheslav Palchevskiy; Scott Hu; S Samuel Weigt; Eileen Liao; Ariss Derhovanessian; Rajeev Saggar; Sophie Song; Robert Elashoff; Otto O Yang; John A Belperio
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

10.  The construct validity of the health utilities index mark 3 in assessing health status in lung transplantation.

Authors:  Maria-Jose Santana; David Feeny; Sunita Ghosh; Ronald G Nador; Justin Weinkauf; Kathleen Jackson; Marianne Schafenacker; Dalyce Zuk; Grace Hubert; Dale Lien
Journal:  Health Qual Life Outcomes       Date:  2010-09-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.